"The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced.
Adalimumab is the first and o"...
Carteolol Hydrochloride (carteolol) Ophthalmic Solution 1% has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications.
DOSAGE AND ADMINISTRATION
The usual dose is one drop of Carteolol Hydrochloride (carteolol) Ophthalmic Solution 1% in the affected eye(s) twice a day. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine or dipivefrin, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted.
Carteolol Hydrochloride (carteolol) Ophthalmic Solution USP, 1% is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 61314-238-05), 10 mL (NDC 61314-238-10) and 15 mL (NDC 61314-238-15).
Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light.
Dist. by: FALCON Pharmaceuticals, Ltd. Fort Worth, Texas 76134, USA. Mfd. by: ALCON LABORATORIES, INC. Fort Worth, Texas 76134, USA. FDA Rev date: 5/22/2001This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/29/2008
Additional Carteolol Hydrochloride Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.